University of Massachusetts Boston

ScholarWorks at UMass Boston
Doctor of Nursing Practice Scholarly Projects

Nursing

Spring 5-16-2022

Revision and Deployment of an Oral Anticancer Medication
Adherence Toolkit
Kristine LeFebvre
University of Massachusetts Boston, kristine.lefebvre001@umb.edu

Follow this and additional works at: https://scholarworks.umb.edu/nursing_dnp_capstone
Part of the Other Nursing Commons

Recommended Citation
LeFebvre, Kristine, "Revision and Deployment of an Oral Anticancer Medication Adherence Toolkit" (2022).
Doctor of Nursing Practice Scholarly Projects. 7.
https://scholarworks.umb.edu/nursing_dnp_capstone/7

This Open Access Capstone is brought to you for free and open access by the Nursing at ScholarWorks at UMass
Boston. It has been accepted for inclusion in Doctor of Nursing Practice Scholarly Projects by an authorized
administrator of ScholarWorks at UMass Boston. For more information, please contact library.uasc@umb.edu.

1

Revision and Deployment of an Oral Anticancer Medication Adherence Toolkit
Kristine B. LeFebvre, DNP, RN, NPD-BC, AOCN
College of Nursing and Health Science, University of Massachusetts Boston
May 12, 2022

Submitted in Partial Fulfillment of the Requirements for the Doctor of Nursing Practice Degree
Project Advisors
Faculty Advisor: Eileen M. Stuart-Shor, PhD, ANP-BC, FAHA, FAAN
Site Advisor: Michele Galioto, DNP, RN, CNS
Second Reader: Sarah J. Miano, PhD, RN

2

Abstract
BACKGROUND: Oral anticancer medications offer state-of-the-art cancer treatment with the
convenience and autonomy of self-care in the home. Professional organizations often provide
expert guidance and resources to support the provision of high quality, safe, evidence-based care.
LOCAL PROBLEM: Many institutions lack a formal oral anticancer medication program,
including a process to assess and monitor adherence. Nurses and their colleagues look to the
literature, training, collaboration with colleagues, and through practice tools and programs
available through their specialty associations for support in their adherence work. The Oral
Adherence Toolkit released in 2016 needed updating to reflect current best practices.
METHODS: The Chronic Care Model underlies this quality improvement project to design and
deploy tools on a national professional oncology nursing site. The change in practice was
informed by Lewin’s Change Management Model.
INTERVENTIONS: Utilizing baseline results from a pre-implementation survey, expert
feedback, and evidence-based literature, of the 14 tools in the Oral Adherence Toolkit, one tool
was removed and 13 revised. Two new tools were added, resulting in 15 distinct tools in the
newly named Oral Anticancer Medication Toolkit. The revised toolkit was deployed on the
website of the specialty nursing organization.
RESULTS: A post-implementation survey indicated that the revised toolkit improved in relation
to applicability to practice. The new toolkit has been deployed on the organizational website
where downloads are monitored.
CONCLUSIONS: Nurses and their colleagues require resources available to support care of
individuals taking oral anticancer medications. The revised toolkit provides evidence-based,
relevant, tailored resources to support practice.
Key Words
Oral anticancer medications; oral chemotherapy; oral antineoplastic medications, oral oncolytics,
adherence; toolkit; practice tools
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Revision and Deployment of an Oral Anticancer Medication Adherence Toolkit
Introduction
Oral anticancer medications are widely used in cancer care today. Traditional
chemotherapy, such as cyclophosphamide and capecitabine, targeted agents, including imatinib
and bortezomib, and hormonal agents, such as tamoxifen, have changed the landscape of cancer
care. With more than 100 oral anticancer medications currently approved by the FDA and with
additional medications in development, it is anticipated that the use of oral agents will continue
to rise. Oral anticancer medications offer the patient convenience and autonomy compared to
parenteral treatment. A caveat, however, is that these drugs can have significant side effects,
transfer much of the burden of treatment oversight to patients and their caregivers and are costly.
Despite the life-saving purpose of these drugs, adherence in studies of adults taking oral
anticancer medications is suboptimal. In many studies, 80% or better is considered acceptable
adherence (Greer et al., 2016).
Problem Description
Oral anticancer medication agents are high-risk medications with a narrow therapeutic
index. Without adherence as prescribed, either by taking too much drug (over-adherence) or too
little drug (under-adherence), the dose intensity of the drug is incorrect, leading to adverse
effects and inadequate treatment of disease. Consequences can include an ineffective treatment
regimen, unnecessary change in treatment, increased use of healthcare resources, altered side
effect profile, decreased communication with the provider and healthcare team, and poor overall
survival (Tipton, 2015; Weingart et al., 2008; Levit et al., 2022).
The safety of oral anticancer medications was addressed by the American Society of
Clinical Oncology (ASCO)/ Oncology Nursing Society (ONS) Chemotherapy Administration
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Safety Standards in 2013. The standards were later updated in 2016. They include criteria on
prescribing oral anticancer medication agents and identify the need for a process to monitor
patients for initial and ongoing adherence, and toxicity to oral anticancer medication agents
(Neuss et al., 2017). In 2019, ASCO collaborated with the National Community Oncology
Dispensing Association (NCODA) to write Patient-Centered Standards for Medically Integrated
Dispensing: ASCO/NCODA Standards. This publication includes standards related to oral
anticancer medications such as calling for the use of adherence tools, adherence assessment and
documentation, and a process for follow-up including monitoring for toxicity (Dillmon et al.,
2019).
The literature has identified multiple factors that influence oral therapy adherence. In a
review of more than 150 studies of oral anticancer medications, Irwin and Johnson
(2015) identified personal, treatment, provider and access factors that influence adherence.
Personal factors include age, level of education, depression, and forgetfulness. Treatment factors
include the cost, complexity of the regimen and its duration. The patient’s relationship with the
provider, decision-making involvement, and access to the medication were considered influences
of the health system and care delivery. Personal beliefs and preferences around medication
influences adherence, and how well an individual can continue with self-care. Adherence is
influenced by the patient’s underlying disease or comorbidities, their medication knowledge, and
their amount of social support. Additionally, a positive relationship between patients and
healthcare providers has been found to improve adherence and symptom management
(Dowling, 2019).
Although oral anticancer medications are used widely throughout cancer care, many
institutions do not have a formal oral anticancer medication program, including a process to
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assess and monitor adherence. Oncology nurses have expertise in cancer treatment, patient
education, and symptom management, but the unique requirements of caring for patients taking
oral anticancer medications, assisting to manage their treatment in the home, may be new.
Nurses rely on resources available in the literature, through training and collaboration with
colleagues, and through practice tools and programs offered by specialty organizations to build
and strengthen their patient care programs. To meet this need, in 2016 ONS developed the ONS
Oral Adherence Toolkit. Over time, the evidence has evolved, and the tools now require revision
to assure they are based on the most current evidence and continue to meet the needs of the
nurses and institutions who depend on these resources to guide practice.
Available Knowledge
A Prisma-guided literature search was conducted in the spring of 2020 to address the
PICO question, “Among people treated with oral anticancer drugs, what interventions have been
shown to improve adherence?” Of the 598 citations that were found originally on the limited
search, duplicates were removed, and 385 articles were screened by title and abstract. Of those,
356 citations were excluded, leaving 29 citations for full-text review. Full text review excluded
20 articles; four were study proposals with results not yet available, ten were excluded because
they were not measuring oral anticancer medication adherence, and six were case studies or
quality improvement projects. The search was updated six months later to add one additional
study meeting criteria.
Ten quantitative studies were evaluated and are summarized in Appendix A. Seven are
randomized, controlled trials, one is quasi-experimental, one prospective interventional, and one
non-experimental. All studies used indirect methods to measure adherence, with three using
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more than one method. Self-report was used in four studies, pill count used in four,
pharmacy refill rates were used in four studies, and two used an electronic smart pill bottle.
A total of 1,162 participants were included in the combined studies. Sample sizes were
small overall, ranging from 29 to 270 participants, with three studies of 48 participants or
less. (Byrne et al., 2018; Mauro et al., 2019; Schneider et al., 2014). Average participant age
ranged from 47 to 71 years old, with most participants between the ages of 56 to 62
years. Women outnumbered men in the studies (n=693, 60%). The studies did not collect data
consistently on race or socioeconomic status. All studies were limited to subjects with a
diagnosis of cancer taking an oral anticancer medication.
Non-research evidence was also examined. Several national organizations have
developed resources that can be adapted into practice when caring for patients taking oral
anticancer medications. The Michigan Oncology Quality Consortium (MOQC) has developed
resources for initiating, teaching, and monitoring patients taking oral anticancer medications
(MOQC, n.d.). The National Community Oncology Dispensing Association (NCODA) has
worked with collaborative partners in pharmacy and nursing to develop detailed Oral
Chemotherapy Education tools for patients, and their nursing committee has developed several
documentation tools (NCODA, n.d.). The Association of Community Cancer Centers (ACCC),
in collaboration with an interprofessional workgroup published a white paper in 2016 focused on
organizational approaches to establishing an oral anticancer medications program (ACCC, 2016).
Despite these many options, a need persists for tools and resources designed to assist nurses in
their support of patients taking oral anticancer medications.
The findings in this review are consistent with an analysis of 159 studies by Irwin and
Johnson (2015). In their research, the most common factor to influence medication adherence
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was a positive relationship between the patient and the provider. The next three most common
factors are the management of side effects, the patient’s level of forgetfulness, and the patient’s
belief that the medication is necessary.
Based on this review of the evidence, the most promising intervention to address the local
problem was to develop tools and resources to support oncology nurses in practice. The purpose
of this project was to revise and deploy an oral adherence toolkit, housed on the ONS website
and accessible to a broad audience of oncology providers. The toolkit can be adapted by
oncology nurses in the care of their patients; used for educating, coaching, monitoring toxicities,
and documenting patient status within the medical record.
Rationale
This project was guided by the Chronic

Figure 1: The Chronic Care Model

Care Model. Originally developed in 1996, and
revised in 1998, the Chronic Care Model provides
a structure for improved clinical and functional
outcomes seen in those with chronic illnesses
(Wagner et al., 1996; Wagner, 1998). The model
has been used widely in quality improvement and
is applicable to a variety of illnesses. There are six
components to the model. Community programs
and organizations form alliances with Health

Note. Image from Wagner, E.H. (1998). Chronic disease
management: What will it take to improve care for
chronic illness? Effective Clinical Practice, 1(1). 2-4.

Systems to expand support and care. Care is coordinated within the health system, as evidenced
by leadership support for initiatives and interventions to benefit patients. Coordinated within the
Health System are Self-Management Support, Delivery System Design, Decision Support and
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Clinical Information Systems. Each of these components leads into productive interactions
between an informed, activated patient and a prepared, proactive healthcare team, essential
elements in improving adherence to anticancer medications (Wagner, 2019).
Over the last several decades, cancer has been increasingly viewed as a chronic illness,
with nearly 17 million people in the U.S. living with cancer and its aftereffects (ACS, 2022).
Treatment with oral anticancer medications is best addressed by the proactive approach outlined
in the Chronic Care Model. Encouraging and supporting the patient’s efforts to care for oneself
with their anticancer drugs, tailoring the treatment recommendations within cancer care
guidelines to the patient’s diagnosis and individual needs, clearly defined staff roles in support
for those coordinating care of the individual taking oral anticancer medications, and having
information systems, the ability to track the care in the EHR, to efficiently meet the needs of the
population will produce engaged, activated patients and providers.
The process of implementing this change project was guided by Lewin’s Change
Management Model, which has three stages, unfreeze, change, and refreeze (MindTools, 2020).
In the first stage, unfreeze, the organization prepares for the change through a determination of
need, planning for the change, and collaboration with stakeholders to lay the groundwork for
change. Communication is essential including a knowledge of clinical, administrative, and
documentation effects and barriers must be discussed and planned for. Change occurs during the
change stage, where again, collaboration and communication is essential. It is important to
address questions as they arise and empower those making the change to address challenges as
they occur. In the refreeze stage, the change is hardwired into the organization as process.
Although it appears Lewin’s model is simple for today’s complex organizations, there is a great
deal of detail that occurs at each stage.
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Specific Aims
The overall goal of this quality improvement project is to design and deploy tools on a
national, professional oncology nursing website to assist nurses and other oncology clinicians in
monitoring and counseling adult patients taking oral anticancer medications. Several objectives
will be addressed.


Assess clinician satisfaction with the tools available in the current ONS Oral Adherence
Toolkit.



Revise the oral adherence toolkit based on the state-of-the science and identified needs of
nurses in practice.



Deploy the updated oral anticancer medication toolkit on the ONS website.



The revised toolkit will be available for download from the organization’s website.

Methods
Context
This project took place in the setting of a national oncology nursing specialty association
based in the United States. The organization has over 35,000 members including registered
nurses, student nurses, and other healthcare professionals, and is dedicated to excellence in
patient care, education, research, and administration in oncology nursing. Members and are
located across the United States and Canada and in many countries around the world.
The nursing organization is committed to its mission to promote excellence in oncology
nursing and its vision to lead the transformation of cancer care. The organization provides a
professional community for oncology nurses; develops evidence-based resources and education
programs, as well as treatment information; and advocates for patient care—all to improve
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quality of life and outcomes for patients with cancer and their families. The organization works
with the cancer community to reduce the risks, incidence, and burden of cancer by encouraging
healthy lifestyles, promoting early detection, and improving the management of cancer
symptoms and side effects throughout the disease trajectory.
The organization has done considerable work on the topic of antineoplastic therapy for all
routes of administration. This work includes books, journals, educational activities, position
statements, standards, guidelines, and practice resources. Oral anticancer medication
administration is the topic of multiple publications and resources as well. One of these resources
is an oral adherence toolkit.
The administration of oral anticancer medications poses unique challenges to both the
patient and the healthcare team. Refer to the microsystem assessment in Appendix B for detail on
the adult patient’s perspective of the system for oral anticancer medication management. The
diagram notes patient-specific healthcare needs to be addressed before and during oral anticancer
medication administration. These include a pre-treatment assessment to ensure the meds can
physically be safely taken, as well as the psychosocial resources needed to manage the schedule
and drug. Patients on oral anticancer medications interact with many people on the healthcare
team in addition to the oncologist. Depending on the setting, the patient may meet with an
advanced practice provider, a pharmacist, a nurse navigator, or nurse (may or may not be an
infusion nurse), a financial coordinator or counselor, and possibly a pharmacist from a specialty
pharmacy. As part of the monitoring of the side effects and disease, patients will often need to
have testing done, labs or radiology. Patients and their families often require guidance to help
navigate the issues related to their treatment and to receive support needed to remain on therapy.
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A successful oral anticancer medications program requires an established process, with
delineation of roles and responsibilities, as well as effective communication between roles. The
Flow Chart in Figure 2 provides an example of how a practice setting could map out their
process. Many of these steps are recommended by the ASCO/ONS Chemotherapy
Administration Safety Standards, designed to enhance patient safety when receiving anticancer
medication medications (2017). Once mapped out, the interprofessional healthcare team can
analyze each step in the process to determine where the system is working and where there are
opportunities for

Figure 2: Flow chart

improvement.
The patient
experience begins with
the initial appointment.
This key step requires an
organized scheduler with
access to several professional schedules who will listen to the needs of the patient. Timing is
critical for those with a new diagnosis of cancer, often anxious to see the oncologist promptly
and begin therapy as soon as possible.
Before beginning an oral anticancer medication, an assessment of the patient’s physical,
cognitive, and psychosocial needs and abilities is required. It must be confirmed that patients are
able to obtain their medication and take it as scheduled, swallow the pills they are prescribed,
that they can safely store medication, that they have the ability to or the support available to
monitor for side effects, including access to supportive medications and care, and report
concerns to the healthcare team.
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When starting oral anticancer medications, the treatment plan must be communicated
with the healthcare team. The chemotherapy safety standards have identified elements that
should be present in each treatment plan and communicated with each order of oral anticancer
medications (Neuss et al., 2017).
Before beginning any cancer treatment, documentation of consent must be found within
the medical record (Neuss et al., 2017). This may be as a narrative note or an institution-specific
consent form that is signed and included in the record. Rules around consent will vary from state
to state and are addressed differently in each practice setting.
The next step in the process is to order the medication. This is often done through the
electronic ordering system, but there are many practices where a simple prescription is written
and handed to the patient to be filled. To improve patient safety, the safety standards recommend
pre-printed order sets (Neuss et al., 2017). However, each setting determines the optimal process
for their setting. The oral anticancer medication order should be accompanied by required
elements of the treatment plan to permit for the drug and dose verification process to occur prior
to the pharmacy filling the prescription.
Most oral anticancer medications are extremely expensive, costing thousands of dollars
every month. Staff are responsible to obtain approval for medication from the insurer. In most
cases, they will also investigate other sources of financial support, such as manufacturer’s
assistance programs and foundations. Many centers have removed this responsibility from the
clinical staff, hiring financial counselors or coordinators to focus their time on this task, freeing
up the nurse to concentrate on the care of the patient.
Comprehensive patient education is essential for those taking oral anticancer
medications. The safety standards note that education should be both verbal and written, and
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cover select topics (Neuss et al., 2017). In any given practice, comprehensive education may be
provided by an advanced practice provider, registered nurse, or pharmacist, or physician. Patient
education resources are available on several websites that the practice setting can draw on to
facilitate the education.
Dose verification is an essential component of patient safety whenever an anticancer
medication is administered. Safety standards note that the antineoplastic medication is verified
when the order is received, upon preparation, and at the time of administration (Neuss et al,
2017). Verification must occur with oral anticancer medications, ensuring two qualified
professionals confirm the correct drug, calculate the dose, and confirm patient identification to
increase patient safety.
Although some practices and hospitals dispense oral anticancer medications from inhouse dispensing pharmacies, many patients receive their medications from a specialty
pharmacy. Patients and their caregivers must be informed about how they will obtain the
medication (pick up or have it mailed), if someone must be home to receive the prescription, how
refills will be handled, and who the patient should reach out to if they have a problem or concern.
There are times when a specialty pharmacy may augment the work of the practice setting and
others when there is little to no communication between the team and the pharmacist, leaving the
patient unsupported.
Each practice setting determines how they will monitor adherence for their patients
taking oral anticancer medications, determining who will contact patients, when, and what the
process entails. The safety standards require contact within one week of the start of the
anticancer medication (Neuss et al., 2017). Several factors can make it challenging to confirm
the drug start date, monitor, and document adherence within the medical record.
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Symptom management may be part of the adherence monitoring or handled separately.
Patients should be taught how to manage mild symptoms and when and how to report more
severe symptoms to the healthcare team. Patients should be provided with 24-hour access to the
healthcare team to assist with questions as needed.
Collaboration and communication between care providers and other systems is necessary
to assist with transitions of care, such as home to hospital or hospital to extended care facility.
The nature of the change in care may determine if the oral anticancer medication should be
continued or stopped. If continued, patients often bring the medication with them to the new
setting due to the high cost. As noted, communication with the oncology team is essential during
such transitions. Reviewing the steps in the administration of oral anticancer medications
reinforced the need for resources throughout the process to support nurses and other healthcare
providers as they care for individuals taking these medications.
An oral adherence toolkit was developed by the

Table 1: Toolkit Downloads
Year

Downloads

2017

2698

2018

3443

anticancer medications. The toolkit was well received but

2019

1553

became outdated and was revised in 2016. After the

2020*

924

specialty nursing organization in 2009 to serve as a
resource for healthcare teams caring for those taking oral

revision, the new toolkit remained a highly popular

*Note: Data unavailable July 2020 to
January 2021 due to process change.

resource. Analytics from the organizational website provided the number of downloads as noted
in Table 1: Toolkit Downloads. Although the toolkit has remained popular, use has continued to
decline annually, prompting an assessment for relevancy and possible revision.
The 2016 Oral Adherence Toolkit (Table 2) contained 14 tools that could be adapted into
practice. Each tool was developed based on current standards and available evidence and address
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specific steps in the oral anticancer medication process.
To more fully understand the challenges facing
patients prescribed oral anticancer medications a cause and
effects analysis of barriers to oral anticancer medication
monitoring and coaching was constructed (Appendix C). In
this diagram, people involved in the process are detailed.
Materials are focused around the patient’s ability to obtain
the drug. The patient may interact with the team in many
ways, through nursing oversight, physician, lab, and testing
visits, educational session, and interactions with the
pharmacy. Oversight is shared on teams between nurses,

Table 2: 2016 ONS Oral Adherence
Toolkit
Tool 1. Patient Assessment Checklist
Tool 2. Patient Education
Tool 3. Oral Chemotherapy Ordering
Standards
Tool 4. Pharmacy Descriptions,
Benefits, and Concerns
Tool 5. Reimbursement and Patient
Assistance Resources
Tool 6. Food, Drug and Pathway
Interactions and Effects
Tool 7. Sample Treatment Calendars
Tool 8. Factors Influencing Adherence
Tool 9. Methods Used to Encourage
Patient Adherence
Tool 10. Traditional Counseling
Versus Motivational
Interviewing
Tool 11. Medication Reconciliation
Tool 12. Developing a Process of
Medication Tracking
Tool 13. Readiness to Change Scale
Tool 14. Patient and Provider
Resource List

advanced practice providers, pharmacists, and the oncologist. Effective communication is
essential, between the team and the patient, between team members, with other healthcare
providers, and with the specialty pharmacy. Documentation in the medical record helps increase
overall team communication. This improvement project addressed these factors through the
development of clinical practice resources that can be adapted to support patients taking oral
anticancer medications throughout the care trajectory, regardless of setting.
Driving and restraining forces that could impact successful completion of revising and
deploying the Oral Adherence Toolkit were compared in a force field analysis shown in
Appendix D. Current and potential driving forces are focused on the knowledge that the current
adherence toolkit is considered highly successful, and there is organizational support to complete
updates. The organization is currently working on several oral adherence initiatives, which will
complement the toolkit revisions. Restraining forces include the varied processes found in
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different settings, where nurses may be less involved in oral anticancer medication administration. Potential restraining forces include challenges that may come with implementation,
having the new toolkit designed, advertising, and the possibility that nurses may not accept the
new toolkit or find it helpful. Content experts may not be able to help with the process due to a
lack of interest or competing priorities. None of these restraining forces were unsurmountable
and the driving forces were strong, which contributed to the success of the project.
Intervention
The improvement focused on revising the existing ONS Oral Adherence Toolkit and
implementation occurred in three phases as noted in Figure 3. Each phase corresponds with
Lewin’s Change

Figure 3: Project Implementation Flow Chart

Management Model. In
the pre-implementation
phase (Unfreeze),
collaboration with
content experts
determined the tools that should be changed, the extent of the revisions required, and identified
potential new tools, laying the groundwork for change. Implementation occurred in the second
phase, also known as the Change phase in Lewin’s model. Here, revision of the toolkit took
place. Individual tools were revised and reviewed by experts until the final toolkit was
assembled. A second survey assessed the applicability of the new toolkit in practice, followed by
copyedit, design, layout, and posting on the website. The third and final phase of postimplementation, or Refreeze in Lewin’s model, is where the use of the new toolkit in practice is
measured with website statistics and user data.
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The tools in the ONS Oral Adherence Toolkit were revised through an iterative process
based on the needs of nurses and pharmacists in practice, staff experience, and best available
evidence. The process of revising and deploying the toolkit is detailed in the logic model in
Appendix E. The work drew on many resources at the nursing association. These include a
successful toolkit that has been available since 2016 and the support of the organizational
leadership to complete revisions to the resource.
At the time of the revision, the organization was proceeding with concurrent initiatives
related to oral anticancer medication adherence that informed and supported the toolkit revision.
From this work, an interprofessional panel of subject matter experts was invited to participate in
this improvement project, including: a pre-implementation survey, participation in a one-hour
focus group, and review of newly drafted tools for applicability to practice.
The project leader revised the Oral Adherence Toolkit
based on stakeholder feedback and current evidence. The
revised tools were reviewed following the improvement model
of Plan-Do-Study-Act (PDSA) cycles. PDSA cycles consist of
planning the test or observation (plan), trying it out on a small
scale (do), analysis of the small step (study), making changes
to the process (act) and repeating the cycle, if further
modifications are warranted (Institute for Healthcare
Improvement, 2020). Content experts and stakeholders
identified from the original list of volunteers were recruited to
assist with the PDSA process.

Table 3: ONS Oral Anticancer
Medication Toolkit
Tool 1. Patient Assessment
Tool 2. Oral Anticancer Ordering
Standards
Tool 3. Patient Education
Tool 4. Sample Treatment Plan
Tool 5. Pharmacy Descriptions,
Benefits, and Concerns
Tool 6. Reimbursement and Patient
Assistance Resources
Tool 7. Food, Drug, and Pathway
Interactions and Effects
Tool 8. Sample Treatment
Calendar
Tool 9. Follow-Up and Monitoring
Tool 10. Factors Influencing
Adherence
Tool 11. Tools and Techniques to
Encourage Adherence
Tool 12. Approaching Adherence
Through Motivational
Interviewing
Tool 13. Medication
Reconciliation
Tool 14. Wallet Cards
Tool 15. Patient and Provider
Resource List
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Once the content was in its final form, a post-revision survey was developed to describe
satisfaction with the revised toolkit. Responses were received from both nurses and pharmacists,
to determine the applicability of the new tools into practice. The completed toolkit has been
renamed the Oral Anticancer Medication Toolkit to better reflect the variety of tools within.
Refer to Table 3 for a listing of the tools available in the revised document. The toolkit is
available in PDF format with select tools allowing for independent download. The project leader
has collaborated with the marketing team to coordinate advertisement of the newly revised
document using existing member communications. Deployment of the toolkit was measured by
the toolkit’s presence on the website. The organization’s marketing team will track use through
website analytics.
Measures and Analysis
The overall goal of this quality
improvement project was to design and
deploy tools on a national, professional
oncology nursing site to assist nurses in
monitoring and counseling adult patients
taking oral anticancer medications over a
six-month period. Measures are detailed in
Table 4.
A group of interprofessional content
experts was surveyed at the project start.
The pre-implementation survey asked the
experts to reflect on the Oral Adherence

Table 4: Project Measures
Output/Expected
How Operationalized/
Outcome
Measured
Interprofessional group
Multiple choice, and openexpresses satisfaction,
ended questions to serve as
regarding the tool’s ease baseline for comparison with
of use, applicability to
revised toolkit after revision.
practice, and suggestions
for improvement.
Interprofessional expert
Meeting notes reflect
focus group identifies
consensus agreement on new
tools to enhance toolkit
tools to be designed and added
and improve
to revised toolkit. Focus group
functionality.
to occur within 2 months of
process start.
Oral Adherence Toolkit
Toolkit content revised within
content is revised based
3 months of process start.
on stakeholder feedback
Expert consensus obtained
and evidence-based
during PDSA cycles.
literature.
Interprofessional group
Multiple choice, and openexpresses satisfaction,
ended questions to serve as
regarding the revised
comparison with pretools’ ease of use,
implementation survey.
applicability to practice,
and suggestions for
improvement.
Final toolkit layout is
Completed toolkit available
designed and published
for download within 6 months
to website.
of project start.
Organizational
Number of unique users
customers access and
accessing document.
download revised oral
Number of downloads of
adherence toolkit.
revised toolkit.
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Toolkit and recommend revision of existing tools or tools that should be added to the toolkit.
This group was asked multiple choice and open-ended survey questions. Information gained at
this time served as a baseline for comparison after the toolkit was revised.
Focus group meeting notes detailed consensus decisions on resources needed to support
oral adherence and revisions of existing tools. Nurse content experts were recruited to assist with
the PDSA cycles to finalize tools. The goal was to have content for the revised toolkit finalized
within three months of project start.
A second, postimplementation survey was used after toolkit redesign to address the
applicability to practice of the new tools. The survey reflected the domains reviewed in the preimplementation survey, using multiple choice and open-ended questions, with the measured goal
of increasing each tool’s applicability to practice. An aggregate of comments has been compiled
for future projects.
The Oral Anticancer Medication Toolkit was processed through the copyediting, design,
and layout process consistent with the organizational standards, and finalized for distribution.
The target date of deployment, posting to the organizational website, was within six months of
project start. The marketing team will run monthly reports on the number of unique users
accessing the toolkit and the number of downloads.
Ethical Considerations
This project was developed as a quality improvement initiative and will not be used for
research purposes or designed to address a research problem. As noted in the University of
Massachusetts Clinical Quality Improvement Checklist, Appendix F, the project followed
established techniques used in quality improvement, such as PDSA, and will not follow a
research design or be used for untested standards. The project involved the implementation of an
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established tool, adapted to the needs of this practice setting with the purpose of improving the
process of patient care and supporting existing patient safety standards. There is no funding
involved.
The project or innovation proposed is quality improvement and does not meet the
definition of human subject’s research because it is not designed to generated generalizable
findings but rather to provide immediate and continuous improvement feedback in the local
setting in which the project is carried out. The University of Massachusetts Boston IRB has
determined that quality improvement projects do not need to be reviewed by the IRB.
The project has been discussed with staff at the site, who have approved the project as
quality improvement, designed to improve the process and delivery of care and does not require
IRB approval. There is no specific documentation from the organization required.
Results
Work on this improvement project followed the timeline noted in Figure 4. Following
organizational approval of the project in May of 2021, expert review of the existing toolkit began
with the pre-implementation survey. Concurrent with organizational initiatives related to oral
anticancer

Figure 4: Project Timeline

medication
adherence, an
interprofessional
panel of more
than 80 subject
matter experts was invited to participate. Of those invited, 22 nurses and pharmacists agreed to
take part in at least one aspect of the project.
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A copy of the toolkit and a link to an online survey hosted on the Zarca Interactive
platform (Herndon, VA) was distributed to the 22 volunteers by email, asking for both
qualitative and quantitative information about the toolkit, as noted in Table 5. Two questions
were asked related to each tool in the existing toolkit, the applicability of the tool in practice,
and whether the tool should be revised. Applicability to practice was intended to be approached
on a gradient, selecting only one option of whether the tool
was helpful in practice, would inform practice but not be
directly applicable, or whether the tool was easily applied in
practice, with the goal being that most tools would be easily
applied in practice. Between June 23 and August 12, 2021,
13 experts, a mix of nurses and pharmacists, participated in

Table 5: Survey Questions
1. What is your perception of how
applicable this tool is in
practice? [repeated for each tool]
a. Not helpful in practice
b. Will help to inform practice
c. Easily applied to practice
2. Should [tool] be eliminated,
revised, or kept without changes
and why?
3. What is missing from the ONS
Oral Adherence Toolkit?
4. Please share additional thoughts.

the survey.
Quantitative results from the pre-implementation survey can be found in Appendix G.
Overall, respondents indicated that most of the tools were easily applied to practice or would
help to inform practice. The tool viewed as most easily applied to practice was Patient
Education, (69%; n=9). Other tools seen as more applicable to practice included Reimbursement
and Patient Assistance Resources, (46%; n=6), Sample Treatment Calendars, (46%; n=6),
Methods Used to Encourage Patient Adherence, (46%; n=6), Oral Chemotherapy Ordering
Standards, (46%; n=6) and Medication Reconciliation, (46%; n=6). Tools rated more likely to
help to inform practice rather than be easily applied to practice included Food, Drug and
Pathway Interactions and Effects, (69%; n=9), Factors Influencing Adherence, (69%; n=9),
Patient Assessment Checklist, (62%; n=8), Traditional Counseling Versus Motivational
Interviewing, (62%; n=8), Developing a Process of Medication Tracking, (62%; n=8), and
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Patient and Provider Resource List, (62%; n=8). Tools most rated not helpful in practice
included the Readiness to Change Scale, (31%; n=4), Pharmacy Descriptions, Benefits, and
Concerns, (23%; n=3), and Medication Reconciliation, (23%; n=3).
The second survey question asked whether each of the tools should be eliminated,
revised, or kept in the current format and why? Of the 14 tools, 10 received the highest
percentage of replies to revise, with responses ranging from 38% to 92%. Those receiving the
highest number of votes to keep without changes include the Patient and Provider Resource List,
(54%; n=7) and Traditional Counseling Versus Motivational Interviewing, (46%; n=6). The Oral
Chemotherapy Ordering Standards received an equal number of responses, (46%; n=6) to revise
or to keep without changes. The highest number of votes received to eliminate a tool was the
Readiness to Change Scale, (23%; n=3).
Qualitative results of the survey provided multiple comments for the revision of each
tool. Recommendations were made to add or remove specific content, to clarify content, and to
add resources or links that would be helpful to users. Some suggestions were outside of the scope
of the toolkit, such as training for financial counselors, a list of potential interactions for each
drug, or details of symptom management. New approaches to the content were suggested, as
with a link to training videos on motivational interviewing, or to provide sample tools for
teaching and monitoring patients. Recommendations were made on how to redesign tools, as
with a discussion to provide a blank, fillable treatment calendar, and to re-order the toolkit to
follow patient flow throughout treatment.
Once baseline information was gathered, focus groups were held to enrich the process.
Invitations were sent by email to the same group of 22 content experts. Fourteen volunteers were
divided into two 60-minute focus groups. The first was held on July 20, 2021, attended by 7
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nurses, and the second, on July 28, 2021, included 3 nurses and 4 pharmacists. The focus groups
were used to expand on the feedback and comments received by the survey to date. Discussion
explored topics identified in the survey and potential changes. See table 6 for the focus group
format.
The focus group conversations are summarized
in Appendix H, with several key takeaways. Many of
the experts asked about the purpose of the toolkit,
suggesting that it would serve well as an orientation
tool for new team members or to assist staff in
developing resources or building them into the

Table 6: Focus Group Format
1. Introductions
2. Brief review of survey results including
missing elements
a. Disparities in cancer care and
health equity
b. Financial counseling and
resources
c. Resources for follow-up and
monitoring
3. Reimagine possibilities of a new toolkit
a. Target audience
b. Applicability of tools to
practice
c. Dynamic resources
4. Conclusion

electronic health record. There was a need cited to have tools that were directly applicable to
practice, understanding that the method of applying the tools in practice would vary in each
setting. There is a need for a comprehensive pre-treatment assessment beyond the tool in the
toolkit. Dedicated, knowledgeable staff is needed to address the financial challenges of patients
taking oral anticancer medications, and a training process is needed for financial counselors.
Outside of financial needs, few shared a process in place to address health equity. Some of the
experts in the focus groups noted that they continue to address patient needs assessment into the
education session and with the monitoring and follow-up. Monitoring and follow-up have a
different structure in every setting.
Combined with published literature, each tool was revised based on the guidance
received from the pre-implementation survey and the focus group discussions. Revisions
occurred from August to October of 2021. Edits were unique to each tool in the toolkit and can
be measured from levels 1 to 4. A level 1 revision required minimal changes to content, updating
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or adding references or resources. Level 2 revisions reorganized the existing content to improve
flow and readability, added or removed content, references, or resources. In level 3
revisions, content was changed

Figure 5: Level of Revision

significantly and reorganized.
Level 4 revisions entailed a
complete redesign or was a newly
developed tool. One tool from the
original toolkit, the Readiness to
Change Scale, was eliminated.
The level of revision for
each tool in the new toolkit is noted
in Figure 5. As tools were revised,
three nurses agreed to review the
newly developed tools and provide
comments, participating in a PDSA
process. Further edits were made
until reviewers noted the tools to be
complete.
Once the tools were revised, a post-implementation survey was done to compare clinician
satisfaction and applicability to practice of the revised toolkit. The survey was conducted from
November 10 to December 6, 2021, asking the same questions noted in Table 5 about the tools in
the newly revised toolkit. Survey invitations were sent to the original list of 22 experts, but a
poor response was obtained. The invitation was extended to the Nursing Committee of the
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National Community Oncology Dispensing Association (NCODA) and posted on the ONS AllMember Community. Of these invitations, 23 professionals replied, both pharmacists and nurses,
and 19 responses were received to the survey.
The post-implementation survey revealed that of the 15 tools in the revised toolkit, 11
tools were now noted as easily applied to practice with results ranging from (53%; n=10) to
(74%; n=14). Four tools had the highest number of responses as will help to inform practice, the
Pharmacy Descriptions, Benefits, and Concerns, (63%; n=12), Reimbursement and Patient
Assistance Resources, (53%; n=10), Food, Drug, and Pathway Interactions and Effects, (58%;
n=11), and Patient and Provider Resource List (53%; n=10). In this survey, the second question
of whether the specific tools should be eliminated, revised, or kept without changes, all tools
received the highest number of responses as keep without changes, with results ranging from
(58%; n=11) to (95%; n=18). Overall, the entire toolkit was found to be more easily applied to
practice after the revision, with results increasing from 38% in the pre-implementation survey to
58% in the post-implementation survey.
Appendix G displays results of the two surveys for the individual tools. The tool that
showed the least amount of change with the revision was the Patient Education Tool. In the preimplementation survey, this tool received the largest number of responses (69%; n=9) that it was
easily applied to practice. The post-implementation survey noted roughly the same results, with
(68%; n=13) of respondents reporting that the revised tool was easily applied to practice. All
remaining tools in the revised toolkit saw an increase in the number of respondents noting that
the revised tool is easily applied to practice.
The percent improvement between the surveys was calculated. The range in responses
was 38.46%, from -0.81 for the Patient Education tool to 37.65% for the Developing a Process of
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Medication Tracking tool. The mean increase for application to practice was 18.41%, median
21.86%, and the mode was 22.27%. The percent of increase in the applicability to practice for
each of the tools is noted in Figure 5, and ranges from a decrease of 1.17% for the Patient
Education tool, to 173.8% increase found in the Food, Drug, and Pathway Interactions and
Effects tool.

Figure 6: Percent Improvement in Applicability to Practice

Several steps
in the process were
changed from the
original project
proposal. Rather than
holding focus groups
alone, the pre-implementation survey was added to collect data about the toolkit and use the
focus group time to explore select elements more deeply. In addition, the post-implementation
survey was planned to occur after the new toolkit was posted on the organizational website. This
was moved earlier due to competing priorities within the organization. Copyediting, design, and
layout were completed after the post-implementation survey.
The Oral Anticancer Medication Toolkit was deployed on the ONS website on February
26, 2022, with two tools, the Treatment Calendar and Wallet
Card, available independently for download. See Appendix I
to review the revised toolkit. Use statistics are gathered and
reported out monthly. Analytics for the new toolkit are noted
in Table 7.

Table 7: Toolkit downloads
February 26, 2022 – March 30, 2022
 Unique users on website: 5,019
 Registered users logging into site
to download toolkit: 1,486
 Download Wallet Card: 280
 Download Treatment Calendar: 16
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Discussion
The goal of this project was to design and deploy evidence-based tools that support
clinicians in caring for individuals taking oral anticancer medications. Results of the preimplementation survey and focus groups provided feedback on the use of the tools within the
Oral Adherence Toolkit and helped to inform the redesign with quantitative and qualitative data.
Key findings from both the pre-implementation survey and the focus groups included a desire for
tools that are both dynamic and applicable to practice. Each tool was evaluated independently,
and revisions were made to the toolkit based on expert feedback combined with evidence-based
literature. A variety of tools were included as the literature notes that no single approach to oral
therapy adherence is consistently effective (Zerillo et al., 2018; Waseem, et al., 2022).
The Oral Anticancer Medication Toolkit was rearranged to better reflect the patient’s
flow as they proceed through the treatment experience. Comprehensive assessment of patient
needs and barriers throughout treatment with oral anticancer medications is a key component of
supporting adherence. The Patient Assessment tool in the toolkit has been expanded with
physical, lifestyle, financial, treatment, and social factors shown to affect adherence (Irwin &
Johnson, 2015), resulting in a 51% increase in the applicability of the tool.
The ASCO/ONS Chemotherapy Administration Safety Standards (Neuss et al., 2017)
helped to inform several of the tools in the kit, including the Oral Anticancer Ordering Standards
and the Patient Education tools. The standards provide clinicians with guidance to support safe
practice and quality initiatives. They are also used in certification programs such as the ASCO
Quality Oncology Practice Initiative (QOPI) Certification Program (ASCO, 2020). The Oral
Anticancer Ordering Standards tool was revised to reflect the standards, but also incorporate
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additional safety measures recommended by the experts. As a result, in the post-intervention
survey, those finding the tool easily applied to practice rose by 48%.
The Patient Education tool was rated highly applicable to practice in both the pre- and
post-implementation surveys. Feedback suggested minimal changes, such as adding content on
over-adherence and sample teaching tools, and a link to was added to explore content on health
literacy. The high rating of this tool reflects the importance of patient education in treatment, as
detailed in the chemotherapy safety standards (Neuss et al., 2017) and included in oral anticancer
medication programs (Sivakumaran et al., 2022).
The Sample Treatment Plan was added to the Oral Anticancer Medication Toolkit upon
recommendation of clinical experts. It was developed by the NCODA Nursing Committee and
serves as a means to communicate the treatment plan easily and concisely with the patient. It can
empower individuals in their self-care while addressing treatment factors that influence
adherence. Experts using this tool in practice shared that patients often post the completed
document on their refrigerator for easy access to their treatment plan and follow-up needs.
Supporting activated patients that are engaged in their care is a major tenant of the tools.
Consistent with the domains in the chronic care model, the tools provide the information and
support to facilitate meaningful engagement between healthcare workers and their patients. The
Chronic Care Model promotes independence with one’s anticancer medications. Proactive
follow-up, creating a relationship with patients, and providing them with resources, encourages
individuals to not only safely obtain and take their medications, but to be full participants within
their treatment. Clinicians require systems that support the independence and self-care of those
taking oral anticancer medications. As noted by Sivakumaran and colleagues (2022), a process

29
providing comprehensive care to those taking oral therapies, accounting for each of the needed
steps is essential.
By the nature of their design and purpose, some tools are more directly applicable to
practice than others. After the revision, the next three tools in the toolkit were rated higher as will
help to inform practice than easily applied to practice. These tools are designed to serve as
clinical support for a staff member new to working with oral anticancer medications. For
example, the Pharmacy Descriptions, Benefits, and Concerns tool, providing pharmacy
descriptions, may serve better as a teaching tool. A clinician must hold an understanding of
where a drug is ordered from and why, and how it might change the follow-up and monitoring
needed. The Reimbursement and Patient Assistance Resources tool was noted to provide strong
resources but was not designed as patient-facing document. Rather, it is a tool used by the
clinician to support and guide a patient to the financial resources they need.
The Food, Drug, and Pathway Interactions and Effects tool was also designed to help
inform practice. This tool provides broad information about how drug reactions occur with other
medications, food, or supplements, but it is impractical to list every medication and their
potential interactions. Revisions were made to expand the applicability to practice noting the
importance of consulting with pharmacy colleagues, provide links to review herb and drug
interactions, and provide links to drug-specific information.
Treatment calendars have long been used with oral anticancer medications, as a tool for
both education and follow-up. The Sample Treatment Calendars tool from the Oral Adherence
Toolkit was revised based on expert recommendations. During the focus group, several experts
noted that they were able to generate calendars directly from their electronic health record (EHR)
software. With a push of a few buttons, they could detail a calendar and personalize it for a given
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regimen, but this ability is not present in all settings. Given the large number of treatment
regimens and patient variables, the calendars were too challenging to create in all settings. A
blank calendar that could be filled in by healthcare providers was developed. It is available on
the organizational website within the toolkit and as a stand-alone resource. Applicability to
practice for the Treatment Calendar rose 48% in the revised toolkit.
In a scoping review of 21 oral anticancer medication programs (Sivakumaran et al.,
2022), counseling, follow-up, dedicated clinician contact, and adverse event/toxicity monitoring
were considered elements of an oral adherence program. To address these elements in the Oral
Anticancer Medication Toolkit, the content from the previous tool, Developing a Process of
Medication Tracking, was fully redesigned. Details of follow-up requirements were aligned with
published standards, guidelines, and best practices (Neuss et al., 2017; Belcher, et al., 2022;
Mackler et al., 2019), and links were provided for examples of important elements in the process.
The changes resulted in over a 122% increase in applicability to practice for the new Follow-Up
and Monitoring tool.
An individualized approach is needed to support the patient’s efforts to remain adherent
to their anticancer medications (Waseem, et al., 2022; Zerillo et al., 2018). Revision was
recommended by 54% of survey participants for both the Factors Influencing Adherence and the
Tools and Techniques to Encourage Adherence tools. Qualitative feedback suggested inclusion
of several barriers that were discussed, and several methods of reminders, knowing that each
patient is unique and may need several tools or methods to encourage adherence. After revision,
the Factors Influencing Adherence tool rose in applicability to practice by 71% and the Tools
and Techniques to Encourage Adherence tool rose by 48%.
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Productive interactions between the healthcare team and the patient are essential to the
relationship. The Approaching Adherence Through Motivational Interviewing tool was revised
to support clinicians in their communication. The pre-implementation survey revealed mixed
reviews on whether it should remain in the toolkit. Comments suggested tips on teaching a
novice about motivational interviewing and video scenarios with specific examples on how to
apply the technique in practice. The revised tool focused on the process of motivational
interviewing with links to two training videos and several references to expand one’s knowledge.
The tool’s applicability to practice was increased by 128%. The use of motivational interviewing
in patients taking oral anticancer medications is supported by the ONS Guideline for Adherence
to Oral Anticancer Medications in Persons with Cancer, noting the collaborative and goaloriented nature of motivational interviewing effective as a method of encouraging the patient to
change their behavior (Belcher, et al., 2022).
Safety is a key element in supporting activated and engaged patients, and medication
reconciliation remains an important action for this population. Minor changes were made to this
tool upon revision. The percentage of respondents in the post-intervention survey noting the tool
was easily applied to practice for the Medication Reconciliation tool rose by 14%.
The second tool added to the Oral Anticancer Medication Toolkit is a wallet card. Used
widely in immunotherapy administration, the completed cards communicate vital information
about a patient’s medications and their oncology care team that can be shared at transitions of
care or with new providers. The tool was well received on the post-intervention survey with
(74%; n=14) of respondents noting that it was easily applied to practice.
The final tool in the toolkit is the Patient and Provider Resource List. This list provides
clinicians with a variety of web links to explore. As with the Reimbursement and Patient
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Assistance Resources tool, this tool was not designed as patient-facing resource but will help
clinicians to further support individuals taking oral anticancer medications.
The newly revised toolkit has been redesigned to follow the flow of the patient as they
progress through treatment with oral anticancer medications. It is unique from offerings of other
organizations, but the contents are consistent with the latest literature. Standards in ordering,
patient education, and dispensing are consistent regardless of practice site. Interprofessional
collaboration with pharmacists and nurses from professional organizations provided feedback on
the development of and the need for select tools. Multiple publications served as references and
resources when revising the toolkit. The Oral Anticancer Medication Toolkit is designed to
support healthcare providers with tools that can be adapted to various practice settings, including
tools that are unbranded and require minimal permissions for reproduction. The toolkit can be
used to educate and train healthcare professionals new to the administration of oral anticancer
medications and support those building an oral therapies program in oncology.
Limitations
Questions in the surveys were intended to show how usable the tools in the toolkit are in
practice. They were designed to be on a gradient, from not helpful in practice to will help to
inform practice, to easily applied to practice. However, an argument can be made that these
questions do not fall within a continuum and consideration should be given to separate Likerttype questions if used in future surveys.
There were requested edits that fell outside of the scope of the Oral Antineoplastic
Medication Toolkit, for example, requests for calendar templates for each treatment regimen,
photographic images of each type of pill and packaging of oral anticancer medications, or a table
addressing potential interactions for each medication. Requests were made for tools that could be
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directly integrated into the electronic health record (EHR), but the requirements for entry into the
EHR differ in each setting, as do the resources and the responsibilities of staff members.
Conclusions
The ONS Oral Adherence Toolkit was successfully revised guided by current best
practices and expert opinion. In the first month that it was deployed, 814 people logged into the
website to view the toolkit, indicating the potential for broad application of the toolkit for
oncology practitioners. Going forward, there are several opportunities for further resource
development. In the oral anticancer medication context, topics related to health equity are often
equated to financial coverage for medications and addressed by the financial counselor.
However, issues of access to supportive medications, provider appointments, communication
with the healthcare team, educational materials in multiple languages, and health literacy
screening continue to pose a challenge. Tools and resources are needed for training and support
of financial counselors. An algorithm which includes actions related to insurance, Medicare,
Medicaid, manufacturer, and foundation support was discussed. There is a need for EHR
documentation resources to assess and track patient adherence and follow-up, including a
validated pre-treatment assessment tool with scoring criteria that can be reevaluated and
documented as the patient needs evolve over time. Teamwork is required to determine roles and
ensure patients are not lost in the system, including an established process of monitoring and
follow-up of adherence and toxicity management.
The new Oral Anticancer Medication Toolkit may be used as a resource for those seeking
to develop new tools or new approaches to care within their system. It may also serve as a
training or introduction resource for those beginning to work with oral therapies. Although the
toolkit is designed for use with oral anticancer medications, many of the tools and resources are
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also applicable in other settings, addressing challenges faced in chronic illnesses, such as
diabetes, HIV, or hypertension. The toolkit will be evaluated yearly to ensure links are
functioning and the resources continue to be applicable to the needs of healthcare providers and
their patients.
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Appendix A
Summary Table
Number of studies
Study intervention
Intervention: Tailored coaching and/or teaching protocol
Spoelstra et al. (2013)
Automated voice response telephone calls with
symptom management toolkit with/without
coaching
Krikorian et al. (2019)
Pharmacist intervention – followed a schedule
to reinforce teaching and monitor side effects
Eldeib, Abbassi,
Telephone follow-up intervention
Hussein, Salem and
Sabry (2019)
Mauro, Mathews, and
Smart pill bottle and pharmacist follow-up
Sredzinski (2019)
Byrne, Redmayne, Lam, Pharmacy-led clinic intervention – tracked
Tran, and Chan (2018)
patients and followed up to monitor adherence
and
Schneider, Adams, and
Tailored coaching protocol by nursing
Gosselin (2014)
Vacher et al. (2020)

Therapeutic education program. Electronic pill
bottle cap used to measure adherence.

Lam and Cheung (2016)

Pharmacist intervention with coaching assessed
retrospectively

Quality of study

Findings

IA, 3-arm RCT, multisite, N=119; Female
82 (68.9%); Average age 59.6 years

Highest rates of adherence in arm with coaching.

IB, prospective RCT; N=200; Female 154
(77%); Average age 61.8 years
IB, RCT prospective; N=82; Female 52
(63%); Average age 47.4 years

90-100% adherence in both intervention and control

IB, 2-arm RCT; N=40; Female 18 (45%);
Average age 71 years
IIB, Quasi-experimental pharmacy study
with no control group; N=29; Female
17(58.6%); Median age 61 yrs
IIB, 2-arm RCT; N=48; Female 31
(64.6%); Average age 59.85

100% adherence in study arm.

IIB, prospective interventional study;
N=55; Female 51(93%); Age: < 70 = 39
(71%); > 70 = 16 (29%)
IIIB, retrospective chart review, 2 sites,
N=270; Female 104 (39%); Average age
55.4 years

Intervention: Electronic: Automated telephone or text message intervention
Sikorskii et al. (2018)
Daily automated adherence reminder telephone 1A, 2-arm RCT multicenter; N=239;
calls. Weekly symptom management calls
Female 136 (57%); Average age 61.4
years
Spoelstra et al. (2013)
Automated voice response telephone calls with IA, 3-arm RCT, multisite, N=119; Female
symptom management toolkit with/without
82 (68.9%); Average age 59.6 years
coaching
Spoelstra et al. (2015)
Text messaging intervention – daily text
IB, 2-arm RCT, multisite; N=80; Female
message reminders and weekly symptom
48 (60%); Average age 58.5
questions by text
Intervention: Special pill bottle
Mauro, Mathews, and
Smart pill bottle and pharmacist follow-up
IB, 2-arm RCT; N=40; Female 18 (45%);
Sredzinski (2019)
Average age 71 years
Vacher et al. (2020)
Therapeutic education program. Electronic pill IIB, prospective interventional study;
bottle cap used to measure adherence.
N=55; Female 51(93%); Age: < 70 = 39
(71%); > 70 = 16 (29%)

Higher median adherence in intervention group

Adherence reported as very high. Pharmacist
involvement early in process of benefit
Increased adherence in intervention group, but not
statistically significant. Self-reported adherence rates
higher than pharmacy fill rates
Significant improvement in intervention group. Pill
bottle cap measured adherence rather than
intervention.
Patients with pharmacist intervention

No significant difference in adherence between
groups
Highest rates of adherence in arm with coaching.
No difference in adherence between the two groups

100% adherence in study arm.
Significant improvement in intervention group. Pill
bottle cap measured adherence rather than
intervention.
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Microsystem Assessment
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Cause and Effect Diagram
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Force Field Analysis
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Logic Model
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Appendix F
Clinical Quality Improvement Checklist

CLINICAL QUALITY IMPROVEMENT CHECKLIST
Date:
Project Leader:
2/28/2021
Kristine B. LeFebvre
Project Title:
Revision and Deployment of an Oral Anticancer medication Adherence Toolkit
Institution where the project will be conducted:
Oncology Nursing Society
Instructions: Answer YES or NO to each of the following statements about QI projects.
The specific aim is to improve the process or deliver of care with established/ accepted
practice standards, or to implement change according to mandates of the health facilities’
Quality Improvement programs. There is no intention of using the data for research
purposes.
The project is NOT designed to answer a research question or test a hypothesis and is NOT
intended to develop or contribute to generalizable knowledge.
The project does NOT follow a research design (e.g., hypothesis testing or group
comparison [randomization, control groups, prospective comparison groups, cross-sectional,
case control]). The project does NOT follow a protocol that over-rides clinical decisionmaking.
The project involves implementation of established and tested practice standards (evidencebased practice) and/or systematic monitoring, assessment, or evaluation of the organization
to ensure that existing quality standards are being met. The project does NOT develop
paradigms or untested methods or new untested standards.
The project involves implementation or care practices and interventions that are consensusbased or evidence-based. The project does NOT seek to test an intervention that is beyond
current science and experience.
The project has been discussed with the QA/QI department where the project will be
conducted and involves staff who are working at, or patients/clients/individuals who are
seen at the facility where the project will be carried out.
The project has NO funding from federal agencies or research-focused organizations and is
not receiving funding for implementation research.
The clinical practice unit (hospital, clinic, division, or care group) agrees that this is a QI
project that will be implemented to improve the process or delivery of care.
The project leader/DNP student has discussed and reviewed the checklist with the project
Course Faculty. The project leader/DNP student will NOT refer to the project as research in
any written or oral presentations or publications.

YES

NO

X
X
X

X

X
X
X
X
X

ANSWER KEY: If the answer to ALL these questions is YES, the activity can be considered a Clinical Quality
Improvement activity that does not meet the definition of human research. UMB IRB review is not required.
Keep a dated copy of the checklist in your files. If the answer to ANY of these questions is NO, the project must
be submitted to the IRB for review.
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Appendix G
Pre-Post Implementation Comparison Survey Data
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Appendix H
Focus Group Notes
Focus Group 1: July 20, 2021
Attendance: 7 Nurses
Disparities: There is a need for robust financial counselor and social work support. Need for resources in
multiple languages. Financial counselor support is more robust in some settings than others. Need a dedicated
person. Does the patient have a phone?
Obtaining drugs: How will the patient get their medication? (Could change over time) In-house specialty
pharmacy may have an oncology nurse navigator, financial counselors, language support.
Follow-up: Important to prepare for different levels of health literacy, complex regimens, must be proactive.
Discussed homegrown tracking tools vs. reprint. Institutions must have communication process for dose
modifications and treatment changes.
Nursing role: Help to navigate system. Know patient population. Coordinate oral medications with IV therapy.
Identify points of vulnerability.
Health literacy and education: Important to provide resources for patients to take with them.
Pre-Treatment assessment: Include assessment of sensory deficits. Does patient have phone? Who does pretreatment assessment, when? Often it is the prescriber or done during patient education.
Financial: There is confusion among patients and providers with insurance, pharmacy benefits managers,
Medicare donut hole, and support options. Consider algorithm of financial support approaches.
Target audience? Define in toolkit. Medical background or techs, front office, financial people, new staff to
clinic, not previously exposed to oral oncolytics
Sample documents: NCODA oral oncolytics welcome letter for patients. Pocket card, similar to IO card from
ONS. MOATT tool available from MASCC.
Focus Group 2: July 28, 2021
Attendance: 3 Nurses and 4 pharmacists
Health Equity: Each practice setting must have resources available, such as financial counselors who know the
system and can help with individual patient needs. Must have a knowledge of insurance.
Roles: In addition to the financial counselor, it is helpful to have pharmacy tech and social worker.
Safety: Process needed for dose verification
Pre-Treatment assessment: Informal assessment at intake and planning. Team must ensure they can teach and
support patients.
Education: Supportive care may be required. Need blank calendar, medication action plan
Target audience? Define in toolkit.
Toolkit design: Some tools designed for nurses, others for other members of the team. May be
helpful as an onboarding tool. Highlight resources that currently exist. Variety of resources, refine
but don't discard tools. Work with HOPA on drug interactions
Individualize: Prepare tools that can be individualized for patients.
Dynamic toolkit requested; Fill in and print out resources
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Appendix I
Oral Anticancer Medication Toolkit

Accessed at: https://www.ons.org/clinical-practice-resources/oral-adherence-toolkit

